The fifth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was published in 2020. The guidelines contain 6 chapters-namely, (1) overview of the guidelines; (2) epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; (3) recurrent epithelial ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; (4) borderline epithelial tumors of the ovary; (5) malignant germ cell tumors of the ovary; and (6) malignant sex cord-stromal tumors. Furthermore, the guidelines comprise 5 algorithms-namely, (1) initial treatment for ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; (2) treatment for recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer; (3) initial treatment for borderline epithelial ovarian tumor; (4) treatment for malignant germ cell tumor; and (5) treatment for sex cord-stromal tumor. Major changes in the new edition include the following: (1) revision of the title to "guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer"; (2) involvement of patients and general (male/female) participants in addition to physicians, pharmacists, and nurses; (3) clinical questions (CQs) in the PICO format; (4) change in the expression of grades of recommendation and level of evidence in accordance with the GRADE system; (5) introduction of the idea of a body of evidence; (6) categorization of references according to research design; (7) performance of systematic reviews and meta-analysis for three CQs; and (8) voting for each CQ/recommendation and description of the consensus.

中文翻译：

---

2020年日本妇科肿瘤学会卵巢癌、输卵管癌和原发性腹膜癌治疗指南。

日本妇科肿瘤学会第五版卵巢癌、输卵管癌和原发性腹膜癌治疗指南于2020年出版。指南共分6章，即：（1）指南概述；(2)上皮性卵巢癌、输卵管癌、原发性腹膜癌；(3)复发性上皮性卵巢癌、输卵管癌、原发性腹膜癌；(4) 卵巢交界性上皮肿瘤；(5)卵巢恶性生殖细胞瘤；(6)恶性性索-间质瘤。此外，该指南还包括5个算法，即（1）卵巢癌、输卵管癌和原发性腹膜癌的初始治疗；(2)复发性卵巢癌、输卵管癌、原发性腹膜癌的治疗；(3)交界性上皮性卵巢肿瘤的初始治疗；(4)恶性生殖细胞瘤的治疗；(5)性索间质瘤的治疗。新版主要变化如下：（1）标题修改为《卵巢癌、输卵管癌、原发性腹膜癌治疗指南》；(2) 除医生、药剂师和护士外，患者和一般（男性/女性）参与者的参与；(3) PICO 格式的临床问题 (CQ)；（4）根据GRADE系统改变推荐等级和证据等级的表达方式；(5) 引入证据体系的概念；(6) 根据研究设计对参考文献进行分类；(7) 对三个 CQ 进行系统评价和荟萃分析；